RxDoctor Payments Data

Pedro Camacho Maldonado, MD

Hematology · Gilbert, AZNPI 1861151441

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $175 and has fallen 61.8% since, to $67 in 2025.

$469in general payments, 2019–2025

Across 19 payments — averaging $24.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$79
  • Madrigal Pharmaceuticals$69
  • GSK$49
  • Gilead$47
  • Octapharma USA, Inc.$47
  • Shield Therapeutics Inc$40
  • plus $137 from 7 others

What the payments were for

  • Food & beverage$469100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few hematology providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$83,105
Medicare patients
363
Services billed
1,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban206$259,084
OzempicSemaglutide141$209,879
TrulicityDulaglutide66$92,702
JardianceEmpagliflozin55$67,509
JanuviaSitagliptin Phosphate36$56,589
FarxigaDapagliflozin Propanediol34$42,444
XareltoRivaroxaban27$38,850
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$24,517
TradjentaLinagliptin29$23,172
MounjaroTirzepatide13$20,729
Breo ElliptaFluticasone/Vilanterol21$17,989
NucyntaTapentadol Hcl11$15,574
LinzessLinaclotide20$13,128
Tresiba Flextouch U-200Insulin Degludec13$12,916
Lantus SolostarInsulin Glargine,hum.Rec.Anlog76$11,646

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$79$209,879141 claims
Lilly USA, LLCTrulicity, Mounjaro$16$113,43179 claims
GSKTrelegy Ellipta, Breo Ellipta$49$42,50647 claims
Johnson & JohnsonXarelto$19$38,85027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Arizonaon file to place this against a meaningful peer group, so we don't.

Other hematology in Gilbert

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →